yeah i also queried as to why only a small number of patients were reported on, however after further research, the only 2 main endpoints as defined by the study are 1. safety & 2. proteinuria reduction of 50% or more above standard of care.
so 3/11 saw reductions of 50% or more...if there were others with reduction of say 30% (still a great result), then this was not reported as it did not fall within the endpoints defined by the study.
I reckon once results are released, we will know the number of both those 50% or more in addition to a general, overall average of all participants in the trial.
if only they didn't raise $$$ at such ridiculous levels.
What up? DXB- no other way.., page-24
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.010(2.20%) |
Mkt cap ! $247.9M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.8¢ | 43.8¢ | $701.3K | 1.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 111371 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 8072 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |